Inhibitor Therapeutics (OTCMKTS:INTI) Posts Quarterly Earnings Results

Inhibitor Therapeutics (OTCMKTS:INTI) released its earnings results on Friday. The company reported $999.00 earnings per share (EPS) for the quarter, Zacks reports.

Inhibitor Therapeutics Price Performance

Shares of INTI stock remained flat at $0.08 during trading hours on Friday. The company’s 50-day moving average price is $0.09 and its two-hundred day moving average price is $0.07. Inhibitor Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.12. The firm has a market cap of $14.35 million, a PE ratio of -8.30 and a beta of -0.58.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc and changed its name to Inhibitor Therapeutics, Inc in August 2019.